NCI-2024-01143

A Randomized, Double-Blind PHase 2/3 Study of Fianlimab (Anti-Lag-3 Antibody), Cemiplimab (Anti-PD-1 Antibody), and Chemotherapy Versus Cemiplimab and Chemotherapy in Frist-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Irrespective of PD-L1 Expression Levels

It's a Phase 2/3 study on a new immunotherapy drug called Fianlimab, comparing a combiantion of Fianlimab, Cemiplimab (an Anti-PD-1 Antibody), and chemotherapy to only Cemiplimab and chemotherapy in treating advanced non-small cell lung cancer (NSCLC). This research is double-blind, meaning both the researchers and participants are unaware of who is receiving each treatment.

an Anti-PD-1 Antibody: Blocks a specific protein (PD-1) that cancer cells use to hide from the immune system. By blocking this protein, the medicine makes it easier for the immune system to find and attack the cancer cells.

non-small cell lung cancer: A type of lung cancer with non small cells that grow too much and can spread to other parts of the body

double-blind: Neither the patients nor the doctors know who is getting what treatment. This helps make sure the results are completely not biased

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05800015

Clinical Trial Site: Sinai

To see all available clinical trials click here.